1. 32 Laboratory Evaluation for Therapy-Related Myeloid Neoplasia-Associated Changes After Autotransplant for Multiple Myeloma. (11th January 2018) Authors: Guillory, Tesha; Almaula, Dhwani; Saxe, Debra; Nooka, Ajay; Jaye, David Journal: American journal of clinical pathology Issue: Volume 149(2018)Supplement 1 Page Start: S180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. (9th June 2018) Authors: Mullane, Kathleen M; Winston, Drew J; Nooka, Ajay; Morris, Michele I; Stiff, Patrick; Dugan, Michael J; Holland, Henry; Gregg, Kevin; Adachi, Javier A; Pergam, Steven A; Alexander, Barbara D; Dubberke, Erik R; Broyde, Natalya; Gorbach, Sherwood L; Sears, Pamela S Journal: Clinical infectious diseases Issue: Volume 68:Number 2(2019) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. (28th May 2021) Authors: Quach, Hang; Nooka, Ajay; Samoylova, Olga; Venner, Christopher P.; Kim, Kihyun; Facon, Thierry; Spencer, Andrew; Usmani, Saad Z.; Grosicki, Sebastian; Suzuki, Kenshi; Delimpasi, Sosana; Weisel, Katja; Obreja, Mihaela; Zahlten‐Kumeli, Anita; Mateos, Maria‐Victoria Journal: British journal of haematology Issue: Volume 194:Number 4(2021) Page Start: 784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Issue 1 (January 2022) Authors: Usmani, Saad Z; Quach, Hang; Mateos, Maria-Victoria; Landgren, Ola; Leleu, Xavier; Siegel, David; Weisel, Katja; Gavriatopoulou, Maria; Oriol, Albert; Rabin, Neil; Nooka, Ajay; Qi, Ming; Beksac, Meral; Jakubowiak, Andrzej; Ding, Bifeng; Zahlten-Kumeli, Anita; Yusuf, Akeem; Dimopoulos, Meletios Journal: Lancet oncology Issue: Volume 23:Issue 1(2022) Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. (December 2022) Authors: Nowatzke, Joseph; Guedeney, Paul; Palaskas, Nicholas; Lehmann, Lorenz; Ederhy, Stephane; Zhu, Han; Cautela, Jennifer; Francis, Sanjeev; Courand, Pierre-Yves; Deswal, Anita; Ewer, Steven M.; Aras, Mandar; Arangalage, Dimitri; Ghafourian, Kambiz; Fenioux, Charlotte; Finke, Daniel; Peretto, Giovanni... Journal: European journal of cancer Issue: Volume 177(2022) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Description of the types and content of phase 1 clinical trial consent conversations in practice. (December 2015) Authors: Wall, Louisa; Farmer, Zachary Luke; Webb, Margaret White; Dixon, Margie D; Nooka, Ajay; Pentz, Rebecca D Journal: Clinical trials Issue: Volume 12:Number 6(2015) Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Plerixafor in combination with granulocyte–colony‐stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Issue 10 (2nd September 2015) Authors: Jagirdar, Neera; Harvey, R. Donald; Nooka, Ajay; Flowers, Christopher; Kaufman, Jonathan; Lonial, Sagar; Lechowicz, Mary Jo; Langston, Amelia; Lipscomb, Carol; Gaylor, Cynthia; Waller, Edmund K. Journal: Transfusion Issue: Volume 55:Issue 10(2015) Page Start: 2351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. Issue 6 (6th November 2014) Authors: Barbee, Meagan S.; Nooka, Ajay; Kaufman, Jonathan L.; Kim, Sungjin; Chen, Zhengjia; Heffner, Leonard T.; Lonial, Sagar; Harvey, R. Donald Journal: Cancer Issue: Volume 121:Issue 6(2015) Page Start: 853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Registering a CD38 antibody upfront for multiple myeloma. Issue 10192 (6th July 2019) Authors: Hofmeister, Craig C; Nooka, Ajay; Kaufman, Jonathan L; Lonial, Sagar Journal: Lancet Issue: Volume 394:Issue 10192(2019) Page Start: 3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. Issue 22 (10th October 2018) Authors: Chehab, Sarah; Zhang, Chao; Panjic, Elyse H.; Chen, Zhengjia; Kaufman, Jonathan L.; Lonial, Sagar; Nooka, Ajay; Harvey, R. Donald Journal: Cancer Issue: Volume 124:Issue 22(2018) Page Start: 4358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗